In the era of "With Corona," non-face-to-face healthcare solution startups stand out.

As revealed in the process of developing the COVID-19 vaccine, the need for efficient and reliable clinical trials is more urgent than ever. JNPMEDI is working on a platform service development project to upgrade domestic medical infrastructure at the level of a medical data platform. The company provides a platform for collecting and monitoring medical data such as digital technology-based clinical trials such as blockchain and cloud and deriving analysis results.

As shown in the process of developing the COVID-19 vaccine, the need for efficient and reliable clinical trials is more necessary than ever.

JNPMEDI is carrying out and preparing a project to upgrade its domestic medical infrastructure to the level of a medical data platform. JNPMEDI provides a platform service that collects and monitors medical data such as clinical trials based on digital technologies such as blockchain and cloud and derives analysis results.

Expectations for the non-face-to-face healthcare industry are rising after the COVID-19 pandemic because it is considered one of the leading industries to lead the "non-face-to-face economy" that has become a daily routine amid the threat of infectious diseases.

According to the Economic Research Institute of KPMG Samjong Accounting Corp., the global non-face-to-face medical market has grown 14.7% annually since 2015 and is expected to reach $41.2 billion (about 48 trillion won) this year. Telemedicine was temporarily implemented in Korea in the COVID-19 situation, and discussions on the introduction of new non-face-to-face medical solutions such as "digital treatment" and "medicine delivery" began in earnest.

In line with this trend, the three startups that have entered the non-face-to-face medical service market are as follows.

Maven Clinical Cloud

QSTAG Dreaming of the Smart Home Care Era

QSTAG, a digital healthcare startup that is developing affordable smartphone-linked medical devices, has launched a "smart urine test paper" that can detect abnormal signs of biomarkers such as protein, glucose, occult blood, and pH in urine as its first product.

This product can be easily tested for urine at home. When the urine test paper is taken with a dedicated smart app, the results diagnosed through an internal algorithm are analyzed and converted into data. Based on this, periodic test results are shown in a graph and health status is monitored. QSTAC is currently developing various smart home care medical devices, and through this, it plans to provide "self-care" services that individuals can examine themselves at home. In recognition of its technology and growth potential, the company was selected as one of the 60 "Baby Unicorn" companies of the year by the Ministry of SMEs and Startups.

'Cloud Hospital' connects hospitals and patients around the world.

Cloud Hospital is a medical solution platform company that enables face-to-face and non-face-to-face telemedicine by matching hospitals, medical staff, and patients around the world. It transparently discloses information on hospitals, doctors, medical expenses, and diseases, and supports medical staff to communicate online. It also provides medical information in multiple languages so that patients can easily know medical information. Through this, it is easy to search what hospital the patient is suffering from, who is a famous medical staff for the disease, and whether it is possible to treat it at an appropriate price.

According to the company, the platform shortens the process that previously took about three months from searching for hospitals and doctors to appointments and treatments to about a week and lowers the cost of medical treatment to 10-50%. The company plans partnerships with more than 2,000 hospitals in 25 countries by next year.

JNPMEDI, a data-driven clinical trial innovation company

As revealed in the process of developing the COVID-19 vaccine, the need for efficient and reliable clinical trials is more urgent than ever. JNPMEDI is working on a platform service development project to upgrade domestic medical infrastructure at the level of a medical data platform. The company provides a platform for collecting and monitoring medical data such as digital technology-based clinical trials such as blockchain and cloud and deriving analysis results.

JNPMEDI signed a strategic business agreement with Cha University Bundang Medical center's department of global clinical trial in April and decided to cooperate in new drug development and clinical trial research using the "Maven Clinical Data Management System (CDMS)."

In addition, it recently launched "Maven Clinical Outcome Assessment (Maven eCOA)," a solution applied to clinical trials using smartphones and wearable devices and is actively responding to the trend of non-face-to-face clinical trials.